A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease.
about
Novel approaches to inhibition of gastric acid secretionManagement of the patient with incomplete response to PPI therapy.Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidencePotassium Channelopathies and Gastrointestinal UlcerationLong lasting inhibitors of the gastric H,K-ATPaseChallenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec.Protonated form: the potent form of potassium-competitive acid blockersCharacterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).Current trends in the management of gastroesophageal reflux disease: a review.Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor TherapyRandomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese MenEmerging drugs for gastroesophageal reflux disease.Insights into the future of gastric acid suppression.Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation.Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease.Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease.Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!Evolving pharmacological approaches in gastroesophageal reflux disease.Novel therapeutics for gastro-esophageal reflux symptoms.Gastric acid, calcium absorption, and their impact on bone health.Current pharmacological management of gastroesophageal reflux disease.New and future drug development for gastroesophageal reflux disease.Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.Patients with refractory reflux symptoms: What do they have and how should they be managed?Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis.Vonoprazan fumarate for the management of acid-related diseases.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy.The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?Concomitant symptoms itemized in the Reflux Disease Questionnaire are associated with attenuated heartburn response to acid suppression.Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.
P2860
Q24614255-4745309F-879B-4F94-B92C-962FDD9762A3Q27025882-02B80A18-6994-4516-8789-E41AEEC070FAQ28072552-5C72F98B-865D-4922-8932-F6346B04CEB7Q28072892-8E8F1497-9322-46F3-B716-2C02A5293D5DQ28299927-2392C31E-2A0A-4727-AC2E-CDAA1AD6FBB9Q35112456-2FCF43FA-D520-4B85-8255-7F7A887E607BQ35171617-A947233E-53E0-4E73-BFCE-C07B8B3DE860Q35429956-E62FACDC-CFBF-4A2B-AD5E-563EF41E0705Q36107247-2ACEBE59-DE0D-4E78-85D1-9F2E5CBC4B27Q37190537-F0E9F3DA-D056-42BD-993F-A9CBBD315334Q37238180-9AB21D97-0C34-45F3-A6DD-18CF92D17D2DQ37553533-E90FC467-3D36-4658-91CE-AA9531E5DDFDQ37570546-19993CA2-824A-483C-B4D5-42AB84795CC6Q37588492-1403F0FA-021F-44E7-A308-4631BE71CC09Q37696562-55E15FFB-775B-483E-ABB4-01581F89A824Q37745066-634EA4CC-7B1C-4B76-BC6F-9136AD524B32Q37759017-44EF04C8-ED14-4421-81F6-3F31F345F38AQ37871345-526E3FC0-8480-473A-BD4B-B4A1F3059E7EQ38025449-05133932-1053-4C69-892E-5ACC7C3FD746Q38029727-4719E80E-E10C-48A0-A1FD-FAF57FF21DD7Q38057369-AE368D50-59E8-4B54-B42D-69827642BE87Q38072903-0C7B7DA1-051E-4097-8AF3-1A8694A9CC37Q38123482-8BEC901B-34E7-4F5E-B6BF-FD75B4B468ECQ38182103-C54833D4-3B74-4DE4-A638-C853A612BC0CQ38415822-EE7722FD-21F8-40DD-8D7E-4BE7B2A04439Q38572793-74CAE0CD-01EA-4734-A409-491D0D637BD2Q38861693-D9FA232B-BC88-4D42-8A36-E9FBB2CA97B2Q38900694-C7E72176-A0BC-4D77-9039-226C813CED76Q39252347-5F20A022-5AC0-429C-9865-CAC543AB9DB1Q39402205-75D6F3E0-DBCC-46B7-90D1-30CA4F1BFD55Q39746768-5E508756-1628-448C-AB30-4113B2B3FFFCQ41842980-FBE694D0-0495-4597-9B37-E58F32747CF0Q42023861-3E869D61-4DFB-4285-AE6F-5D9FA414DFE6Q42023922-B143AB12-76AE-4C7F-85CF-1FF19B37F199Q42923401-076D03F8-71DC-462A-80DB-452CD43DC871Q43055665-FD8A7C1D-3639-43EF-A9D8-D4BA685BE697Q44030644-FDB5CB3E-59C9-40FA-91E8-8EBFD1D032E7Q48629907-AA823E64-9066-427A-A615-96B5C798772DQ49447901-18F01617-CAA7-4B71-B3D3-67F9DF30B96BQ50129556-4EB7C7B5-23C1-4760-B0B0-C1B073BFF96C
P2860
A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A randomized, comparative tria ...... ith nonerosive reflux disease.
@en
A randomized, comparative tria ...... ith nonerosive reflux disease.
@nl
type
label
A randomized, comparative tria ...... ith nonerosive reflux disease.
@en
A randomized, comparative tria ...... ith nonerosive reflux disease.
@nl
prefLabel
A randomized, comparative tria ...... ith nonerosive reflux disease.
@en
A randomized, comparative tria ...... ith nonerosive reflux disease.
@nl
P2093
P2860
P1476
A randomized, comparative tria ...... ith nonerosive reflux disease.
@en
P2093
Hans Denison
Nimish Vakil
Per Lundborg
Peter J Kahrilas
Stefan Franzén
P2860
P356
10.1111/J.1572-0241.2007.01544.X
P407
P577
2008-01-01T00:00:00Z